BRPI0811309B1 - Métodos in vitro para avaliar uma responsividade do gene apo(a) em uma amostra de ácido nucleico de um indivíduo humano ao tratamento com ácido acetilsalicílico para reduzir o risco de um evento cardiovascular futuro - Google Patents

Métodos in vitro para avaliar uma responsividade do gene apo(a) em uma amostra de ácido nucleico de um indivíduo humano ao tratamento com ácido acetilsalicílico para reduzir o risco de um evento cardiovascular futuro Download PDF

Info

Publication number
BRPI0811309B1
BRPI0811309B1 BRPI0811309-2A BRPI0811309A BRPI0811309B1 BR PI0811309 B1 BRPI0811309 B1 BR PI0811309B1 BR PI0811309 A BRPI0811309 A BR PI0811309A BR PI0811309 B1 BRPI0811309 B1 BR PI0811309B1
Authority
BR
Brazil
Prior art keywords
polymorphism
subject
ncbi
blood sample
risk
Prior art date
Application number
BRPI0811309-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Ridker
Daniel Chasman
Dov Shiffman
Original Assignee
The Brigham And Women's Hospital, Inc.
Celera Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham And Women's Hospital, Inc., Celera Corporation filed Critical The Brigham And Women's Hospital, Inc.
Publication of BRPI0811309A2 publication Critical patent/BRPI0811309A2/pt
Publication of BRPI0811309B1 publication Critical patent/BRPI0811309B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
BRPI0811309-2A 2007-05-09 2008-05-09 Métodos in vitro para avaliar uma responsividade do gene apo(a) em uma amostra de ácido nucleico de um indivíduo humano ao tratamento com ácido acetilsalicílico para reduzir o risco de um evento cardiovascular futuro BRPI0811309B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91685807P 2007-05-09 2007-05-09
US60/916.858 2007-05-09
PCT/US2008/005986 WO2008140776A1 (en) 2007-05-09 2008-05-09 Polymorphism in the apo (a) gene predict responsiveness to acetylsalicylic acid treatment

Publications (2)

Publication Number Publication Date
BRPI0811309A2 BRPI0811309A2 (pt) 2020-09-15
BRPI0811309B1 true BRPI0811309B1 (pt) 2022-03-03

Family

ID=40002550

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811309-2A BRPI0811309B1 (pt) 2007-05-09 2008-05-09 Métodos in vitro para avaliar uma responsividade do gene apo(a) em uma amostra de ácido nucleico de um indivíduo humano ao tratamento com ácido acetilsalicílico para reduzir o risco de um evento cardiovascular futuro

Country Status (7)

Country Link
US (6) US7943317B2 (enExample)
EP (1) EP2150627B1 (enExample)
JP (2) JP5601685B2 (enExample)
CN (1) CN101743325B (enExample)
BR (1) BRPI0811309B1 (enExample)
CA (1) CA2686874C (enExample)
WO (1) WO2008140776A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943317B2 (en) * 2007-05-09 2011-05-17 The Brigham And Women's Hospital, Inc. Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment
WO2013080227A1 (en) * 2011-11-28 2013-06-06 Decode Genetics Ehf Genetic variants useful for risk assessment of arterial disease
US20150227678A1 (en) * 2014-02-09 2015-08-13 Lane Bernard SCHEIBER Method to represent the nucleotide elements of a dna sequence as numerical elements to include adenine being assigned the value one, guanine being assigned the value two, cytosine being assigned the value three, and thymine being assigned the value four

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1806867C3 (de) * 1968-11-04 1974-07-18 Byk-Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung substituierter 4-Hydroxy pyrimidine
US6992171B2 (en) * 2000-06-22 2006-01-31 Takeda Pharmaceutical Company Limited Polypeptide and its DNA
EP2474631B1 (en) 2002-12-20 2014-02-12 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
US7625699B2 (en) * 2003-03-10 2009-12-01 Celera Corporation Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof
CA2832293C (en) * 2003-11-26 2015-08-04 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
US20050287558A1 (en) * 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
US20050287559A1 (en) 2004-05-07 2005-12-29 Applera Corporation Genetic polymorphisms associated with vascular, methods of detection and uses thereof
US7381536B2 (en) * 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient
ATE480229T1 (de) * 2005-05-24 2010-09-15 Flamel Tech Sa Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung
US7972802B2 (en) * 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
WO2008132763A2 (en) * 2007-04-30 2008-11-06 Decode Genetics Ehf Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
US7943317B2 (en) 2007-05-09 2011-05-17 The Brigham And Women's Hospital, Inc. Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment

Also Published As

Publication number Publication date
US20110206667A1 (en) 2011-08-25
US11697850B2 (en) 2023-07-11
US20150284799A1 (en) 2015-10-08
US10550433B2 (en) 2020-02-04
EP2150627B1 (en) 2013-09-11
BRPI0811309A2 (pt) 2020-09-15
CN101743325A (zh) 2010-06-16
US20200248262A1 (en) 2020-08-06
JP5601685B2 (ja) 2014-10-08
US20170335394A1 (en) 2017-11-23
CA2686874C (en) 2021-10-19
US20090004187A1 (en) 2009-01-01
CN101743325B (zh) 2014-07-09
WO2008140776A1 (en) 2008-11-20
EP2150627A4 (en) 2011-02-23
US7943317B2 (en) 2011-05-17
EP2150627A1 (en) 2010-02-10
CA2686874A1 (en) 2008-11-20
US20140024623A1 (en) 2014-01-23
JP2010528262A (ja) 2010-08-19
JP2014036674A (ja) 2014-02-27

Similar Documents

Publication Publication Date Title
Stender et al. Genetically elevated bilirubin and risk of ischaemic heart disease: three M endelian randomization studies and a meta‐analysis
Nicholls et al. Lipoprotein (a) levels and long-term cardiovascular risk in the contemporary era of statin therapy
Stocco et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia
Cuisset et al. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting
US20130217743A1 (en) Cancer prevention and treatment methods based on dietary polyamine content
US11697850B2 (en) Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment
Deac et al. A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment
Liu et al. Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review
Song et al. Genetic variants of adiponectin and risk of colorectal cancer
Chen et al. Genetic variants in DDO and PEX5L in peroxisome‐related pathways predict non‐small cell lung cancer survival
Diaz-Barreiro et al. The SLE variant Ala71Thr of BLK severely decreases protein abundance and binding to BANK1 through impairment of the SH3 domain function
Aragonès et al. Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study
PT1651774E (pt) Utilização de polimorfismos na oatp-c humana, associados com um efeito sobre a farmacocinética da estatina, em humanos em terapia com estatina
JP2010528262A5 (enExample)
Tabara et al. No association between INSIG2 Gene rs7566605 polymorphism and being overweight in Japanese population
Xie et al. SLC4A4, FRAS1, and SULT1A1 genetic variations associated with dabigatran metabolism in a healthy Chinese population
Postula et al. Effect of common single-nucleotide polymorphisms in acetylsalicylic acid metabolic pathway genes on platelet reactivity in patients with diabetes
Hogue et al. Genotype of the mutant LDL receptor allele is associated with LDL particle size heterogeneity in familial hypercholesterolemia
Vargas-Alarcón et al. ABO gene polymorphisms are associated with acute coronary syndrome and with plasma concentration of HDL-cholesterol and triglycerides
Tomer et al. Polymorphisms in the IBD5 locus are associated with Crohn disease in pediatric Ashkenazi Jewish patients
Fricke et al. Epidemiology and genetic determination of measures of peripheral vascular health in the Long Life Family Study
Ding et al. Genomic regions that influence plasma levels of inflammatory markers in hypertensive sibships
Zito Liver Transcriptome Analysis in NAFLD Patients
Aquilante et al. Key articles relative to cardiovascular pharmacogenomics
WO2020264023A1 (en) Determination of magnesium body concentration

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/05/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.